BioSpace News Archive

Sosei Group Corporation announces that Idorsia Pharmaceuticals Japan Ltd., a Sosei Group company, has submitted a New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for the approval of daridorexant, a dual orexin receptor antagonist which has been co-developed with Mochida Pharmaceutical Co., Ltd., for the treatment of adult patients with insomnia.

TATAA Biocenter, a leading global CRO for high-quality molecular analysis, announced the formation of its Scientific Advisory Board.

Alzheon, Inc. announced its participation in the upcoming Truist Securities BioPharma Symposium in New York City, New York on November 8-9, 2023.

GE HealthCare, a leading global precision care innovator, reported financial results for the third quarter ended September 30, 2023.

Caris Life Sciences® announced that Atrium Health Levine Cancer, an integrated cancer program that unites cancer services at Atrium Health Levine Cancer Institute and Atrium Health Wake Forest Baptist, has joined the Caris Precision Oncology Alliance™.

SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced the initiation of a Phase I/II clinical trial investigating its intraocular drug delivery platform in patients with glaucoma and visually significant cataracts.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it will release its third quarter 2023 financial results on Tuesday, November 14, 2023 before the open of the U.S. financial markets.

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the third quarter ended September 30, 2023, on Monday, November 13, 2023, after the close of the U.S. financial markets.

Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2023 before the market opens on Tuesday, November 7, 2023.

Galera Therapeutics, Inc. announced that it has received official meeting minutes from the Type A meeting with the United States Food and Drug Administration held September 28, 2023 in which the FDA reiterated the need for an additional Phase 3 trial of avasopasem manganese for radiotherapy-induced SOM.